Matthew Sykes
Stock Analyst at Goldman Sachs
(3.70)
# 737
Out of 4,963 analysts
205
Total ratings
49.3%
Success rate
7.4%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $9.03 | -44.63% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.10 | -26.83% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $14.02 | -53.64% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $33.59 | +33.97% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.94 | +34.68% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $27.19 | +76.54% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.50 | +3.03% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $174.00 | -8.05% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.08 | +41.24% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $88.59 | +41.10% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $13.19 | +6.14% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $205.00 | +17.07% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $13.29 | +95.64% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $162.80 | +4.42% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $63.50 | -11.81% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $129.19 | -38.08% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.33 | +12.78% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $163.04 | +16.54% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.71 | +146.55% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.33 | +82.40% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $28.61 | +29.33% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $46.71 | +39.16% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $188.80 | +32.42% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $4.61 | +420.61% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,285.24 | +1.15% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $12.35 | -2.83% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $488.12 | +31.12% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $118.69 | +22.17% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $47.99 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $9.03
Upside: -44.63%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.10
Upside: -26.83%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $14.02
Upside: -53.64%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $33.59
Upside: +33.97%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.94
Upside: +34.68%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $27.19
Upside: +76.54%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.50
Upside: +3.03%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $174.00
Upside: -8.05%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.08
Upside: +41.24%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $88.59
Upside: +41.10%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $13.19
Upside: +6.14%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $205.00
Upside: +17.07%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $13.29
Upside: +95.64%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $162.80
Upside: +4.42%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $63.50
Upside: -11.81%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $129.19
Upside: -38.08%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.33
Upside: +12.78%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $163.04
Upside: +16.54%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.71
Upside: +146.55%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.33
Upside: +82.40%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $28.61
Upside: +29.33%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $46.71
Upside: +39.16%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $188.80
Upside: +32.42%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $4.61
Upside: +420.61%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,285.24
Upside: +1.15%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $12.35
Upside: -2.83%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $488.12
Upside: +31.12%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $118.69
Upside: +22.17%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $47.99
Upside: -